preparation and quality control of 177lu-chitosan for radiosynovectomy

Authors

hassan yousefnia

amir jalilian

fereydoun abbasi-davani

samaneh zolghadri

ali bahrami-samani

abstract

introduction: rheumatoid arthritis (ra) is the most common autoimmune disease, leading to the destruction of the joints and causing pain, disability, and immobility in the patients. radiosynovectomy (rsv) has been applied as an effective treatment for the patients with resistant synovitis after failure of long-term pharmacotherapy and intra-articular steroid injection for more than 50 years. several radiopharmaceuticals have been developed for rsv so far, but still development of new radiophamaceuticals is of crucial interest. in this research, the 177lu-chitosan complex (177lu-chito) was introduced as a new agent for rsv. methods: 177lu was produced by irradiation of a natural lu2o3 target at a thermal neutron flux of approximately 4 × 1013 n/cm2·s. 177lu-chito was prepared in the diluted acetic acid solution. the radiochemical yield was checked by itlc method. the biodistribution of the complex was investigated by intra-articular injection to rabbits’ and rats’ knee joints. the leakage of injected dose from the injection site in the rabbit organs was investigated using spect imaging up to 48 hours. results: 177lu was prepared with a specific activity of 2.6-3 gbq.mg-1 and radionuclide purity of 99.98%. 177lu-chito was prepared successfully with high radiochemical purity (95%) and specific activity of 888 tbq/mmol. both the biodistribution data in rats and spect imaging of the rabbit showed that there was no significant leakage of the injected activity even after 192 h. conclusion: considering all of the excellent features of the complex, this radiopharmaceutical can be used for effective management of synovial inflammation.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Preparation and quality control of 177Lu-chitosan for radiosynovectomy

Introduction: Rheumatoid arthritis (RA) is the most common autoimmune disease, leading to the destruction of the joints and causing pain, disability, and immobility in the patients. Radiosynovectomy (RSV) has been applied as an effective treatment for the patients with resistant synovitis after failure of long-term pharmacotherapy and intra-articular steroid injection for more than 50 years. Se...

full text

Preparation and quality control of Lu-chitosan for radiosynovectomy

Introduction: Rheumatoid arthritis (RA) is the most common autoimmune disease, leading to the destruction of the joints and causing pain, disability, and immobility in the patients. Radiosynovectomy (RSV) has been applied as an effective treatment for the patients with resistant synovitis after failure of long-term pharmacotherapy and intra-articular steroid injection for more than 50 years. Se...

full text

Development of 177Lu-phytate Complex for Radiosynovectomy

Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. Materials and Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. The product was converted into chloride form which was further used for labeling of 177Lu-phytate complex and che...

full text

Development of 177Lu-phytate Complex for Radiosynovectomy

OBJECTIVE(S) In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. MATERIALS AND METHODS Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 10(13) n.cm(-2).s(-1). The product was converted into chloride form which was further used for labeling of (177)Lu-phytate complex...

full text

Development of Sm-153 chitosan for radiosynovectomy

  Introduction: Developing new radiosynovectomy agents is of great importance due to the aging of human populations around the world and increasing the incidence of inflammatory diseases. In this work, Sm-153 chitosan agent was developed for the first time in our country and preparation and quality control of the compound is described. Methods: Sm-153 chloride was ob...

full text

Production and quality control of 166Ho-Chitosan for therapeutic applications

Introduction: In this research, [166Ho]Holmium chitosan complex production is described in details, followed by determination of complex radiochemical purity, stability and biodistribution (after intra-articular injection) in wild-type male rats. Finally a Ho-166 based chitosan kit for ultimate radiosynovectomy as well as radiotherapy applications was developed. Methods: 166</s...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of nuclear medicine

Publisher: tehran university of medical sciences

ISSN 1681-2824

volume 22

issue 1 2014

Keywords
[ ' c h i t o s a n ' , ' r a d i o s y n o v e c t o m y ' , ' l u ' , 1 7 7 , ' b i o d i s t r i b u t i o n ' , ' s p e c t ' ]

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023